Form 4 for HCA HCA Healthcare
Accepted 2021-11-04 00:00:00 ET · period of report 2021-11-02 · accession 0001209191-21-062999 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-04 | 2021-11-02 | HCA | Whalen Kathleen M | SVP, Chief Ethics Off | M - OptEx | $60.58 | +8,325 | 17.2K | +94% | +$504.3K |
| D | 2021-11-04 | 2021-11-04 | HCA | Whalen Kathleen M | SVP, Chief Ethics Off | S - Sale+OE | $250.48 | -3,815 | 8,877 | -30% | -$955.6K |
| D | 2021-11-04 | 2021-11-02 | HCA | Whalen Kathleen M | SVP, Chief Ethics Off | F - Tax | $248.44 | -4,510 | 12.7K | -26% | -$1.12M |
| DM | 2021-11-04 | 2021-11-02 | HCA | Whalen Kathleen M | SVP, Chief Ethics Off | M - OptEx | $0.00 | -8,325 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-02 | M | A | 3,325 | $47.97 | 12,202 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-04 | S | D | 3,815 | $250.48 | 8,877 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.141 to $250.84, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2021-11-02 | F | D | 4,510 | $248.44 | 12,692 | D | — | — | |
| 4 | Common | Common Stock | 2021-11-02 | M | A | 5,000 | $68.96 | 17,202 | D | — | — | |
| 5 | Derivative | Stock Appreciation Right | 2021-11-02 | M | D | 700 | $0.00 | 0 | D | $47.97 · — to 2024-02-05 | 700 Common Stock | (F3) The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets. |
| 6 | Derivative | Stock Appreciation Right | 2021-11-02 | M | D | 2,625 | $0.00 | 0 | D | $47.97 · — to 2024-02-05 | 2,625 Common Stock | (F2) The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015. |
| 7 | Derivative | Stock Appreciation Right | 2021-11-02 | M | D | 5,000 | $0.00 | 0 | D | $68.96 · — to 2025-02-04 | 5,000 Common Stock | (F4) The stock appreciation rights vested in four equal annual installments beginning on February 4, 2016. |